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The main objective of this study is to determine the current use of lung cancer diagnostic
procedures in two large hospitals in the Netherlands, to explore deviations in guideline
adherence between the hospitals, and to estimate the budget impact of the diagnostic work-
up as well as the over- and underutilization.
Materials & methods
A state transition model for the diagnostic pathway for lung cancer patients was developed
using existing clinical practice guidelines (CPG) combined with a systematic literature. In
addition to the CPGs depicting current practice, diagnostic utilization was gathered in two
large hospitals representing an academic tertiary care hospital and a large regional teaching
hospital for patients, who were selected from the Netherlands cancer registry.
Results
The total population consisted of 376 patients with lung cancer. Not in all cases the guideline
was followed, for instance in the usage of MR brain with stage III lung cancer patients (n =
70). The state-transition model predicts an average budget impact for the diagnostic path-
way per patient estimated of € 2496 in the academic tertiary care hospital and € 2191 in the
large regional teaching hospital.
Conclusion
The adherence to the CPG’s differed between hospitals, which questions the adherence to
CPG’s in general. Adherence to CPG’s could lead to less costs in the diagnostic pathway for
lung cancer patients.
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Introduction
Lung cancer is characterized as one of the most malignant tumors with significant mortality
and a large health and economic impact. The incidence in western countries is about 0.04 per-
cent, which is around 12 percent of all new cancer diagnoses [1]. Lung cancer has a bad prog-
nosis with an average survival rate of fifteen percent in five years [2]. The prognosis is often
worse, because a majority of cases present with advanced stage disease—when treatments can
rarely achieve cure[3,4].
Several countries have implemented lung cancer diagnostic and treatment guidelines. The
diagnostic guidelines can support the development of fast and efficient care pathways, which
are required, because a fast and early diagnosis can lead to a better prognosis [5,6]. Roughly,
the pathway can be divided into three parts: imaging, invasive examination and functional
examination. Imaging includes X-ray, CT and PET/CT and invasive examination; acquiring
tumor tissue via endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS), cervical
mediastinoscopy or a CT guided biopsy.
Several changes in lung cancer diagnostics are currently investigated, including early detec-
tion by means of population based screening of high-risk patients. Moreover, the influence of
demographic changes such as an ageing population, and the implementation of mutation pro-
filing such as EGFR and ALK testing will have impact on the need for and amount of diagnos-
tic procedures. These changes will influence the required resources, hence the care pathway is
challenged for efficiency.
As an illustration, several countries are working toward implementation of early detection by
means of screening. Yet, screening programs are known for their down-stream effects on hospital
resources, because patients are submitted for additional diagnostic procedures which allow identi-
fication of tumors and possible metastases, both by physical examination as well as via biopsy [7].
In addition, several high-sensitive technologies are being developed to detect early stage malignan-
cies, such as the detection of methylated DNA [8,9], cell-free DNA [10] or Circulating Tumour
Cells [11,12]. Such technologies will impact the current health system, both in terms of early
detection, hopefully leading to an increased survival, as well as an expected increase in the number
of patients submitted for further diagnostic procedures and potentially treatment.
The main objective of this study is to determine the current use of diagnostic procedures in
two large hospitals, to explore guideline adherence, differences between these hospitals and to
estimate the budget impact of the diagnostic work-up as well as the over- and underutilization
of lung cancer diagnostic procedures.
Methods
Diagnostic pathway
As the basis for the transition model the diagnostic pathway was defined and expressed in a
flowchart, based on the clinical practice guidelines (CPG). This study assumes the clinical
practice guidelines for lung cancer do represent current diagnostic practice. Experts, such as
chest physicians and nurse practitioners, are consulted in addition to these CPG’s to see
whether these guidelines are used in practice and which deviations occur. The information
gained from CPG’s is combined with results from a systematic literature search for diagnostic
procedure models to create an overview for the model.
Current diagnostic practice
In addition to the CPGs depicting current practice, two large hospitals representing an aca-
demic tertiary care hospital and a large regional teaching hospital were selected to collect
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diagnostic resource utilization. Patients diagnosed in 2012 with lung cancer were selected
from the Netherlands Cancer Registry (NCR). The NCR collects data on patient, tumor (i.e
stage according to the TNM system[13], treatment and vital status of all malignancies in the
Netherlands based on pathology notification and hospital discharge registries[2]. Detailed data
on diagnostics were gathered directly from the patient files in the two participating hospitals.
Every patient was followed through the diagnostic pathway to see what modalities were used
in practice.
This one-year cohort is assumed to be representative for the in-hospital diagnostic proce-
dures in lung cancer, and is used in the state-transition model to generalize to prospective
patients.
State transition model
For the development of the state transition model frequencies of use of diagnostic modalities
were determined, using patient level data. These are combined in a model, in which states are
based on investigations or tests that lead to the stages of the TNM staging system[13]. The
TNM staging system consists of the presence of a tumor (T), occurrence of lymph node
involvement (N) and existence of metastases (M). The starting point in the model is the suspi-
cion for lung cancer. The overall endpoint is the TNM stage of the tumor, which can also be
the absence of malignancies. This state-transition model [14] of the diagnostic pathway is
developed and built in Microsoft Excel (Redmond, Washington, 2010). The model uses tariffs
from Dutch Healthcare Authority (NZa), which are acquired via the NZa cost application.
Statistical analysis
A beta distribution is used for the usage rates in the model due to the binomial nature of these
parameters. A chi-squared test is used in SPSS (IBM Corp., Armonk, NY, 2013) to assess inde-
pendence of the usage rates in both hospitals.
Results
The total pathway for patients with suspected lung cancer which is modeled consists of 20 dif-
ferent modalities. A population consisting of 376 consecutive patients with lung cancer
selected in two hospitals (two large hospitals representing an academic tertiary care hospital
and a large regional teaching hospital) is used to assess the diagnostic pathway of lung cancer
diagnosis. Table 1 gives an overview of both the populations in both hospitals representing a
total of 376 patients, with a mean age of 67 and 65,8 respectively.
Table 1. Population characteristics.
Population characteristics* Large teaching hospital (n = 214) Academic tertiary hospital (n = 162)
Mean age (se) 66.95 (10.335) 65.77 (10.180)




- Squamous cell carcinoma














* Cohort with lung cancer diagnoses in 2012
https://doi.org/10.1371/journal.pone.0189251.t001
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The number and frequency (usage rates) of the diagnostic procedures are listed in Table 2.
The usage rates are depicted as absolute (times used) and relative (percentage of total popula-
tion). Significant differences are seen in the diagnosis for the M parameter, such as the
PET-CT (p = 0.008), the diagnostic CT (p = 0.011) and the MRI of the brain (p = 0.005), the
latter is more often performed at the University Medical Center. This approach provided a bet-
ter risk estimation in case of surgery for early and oligometastatic patients.
The tariffs for each diagnostic procedure are listed in Table 3. Using these tariffs for the
state-transition model leads to an average budget impact for the diagnostic pathway per patient
estimated at € 2496 in the academic tertiary care hospital and € 2191 in the large regional
teaching hospital. These differences are explained by the fact that novel diagnostic modalities
such as mutation profiling, which are carried out more by the academic hospitals.
Differences with guideline adherence are especially seen for the number of MRI brains
used, which is different between both hospitals and not according to the guidelines. With this
casemix, the academic center should have had 27 MRI brains (16.7% of casemix with stage III
tumor), while 47 (21.4%) were actually carried out. Within the tertiary center, this difference is
smaller: 43 according to guidelines (20%), 37 (17.2%) actually carried out. Lastly, a PET/CT is
carried out more often in the academic hospital (p = 0.008), which can be explained by the fact
that the teaching hospital has to refer patients to another hospital for a PET/CT.
Discussion & recommendations
This study summarizes resource use in two large hospitals in the Netherlands, representing an
academic tertiary care hospital and a large regional teaching hospital. The datasets consist of
376 patients, which represent all patients diagnosed with lung cancer in 2012 (162 and 214
respectively). The average costs per patient for the diagnostic pathways ranged between €2200
in the large regional teaching hospital and €2500 in the academic tertiary care hospital, which
ends up to at least ten percent of the yearly costs of lung cancer treatment[15,16].
Table 2. Usage of diagnostic procedures in diagnostic pathway.
Modality Large teaching hospital Usage rate (%) Academic tertiary hospital Usage rate (%) p-value
X-thorax 186 87.7 131 86.1 0.241
PET/CT 155 73.1 133 87.5 0.008
CT 209 98.5 147 96.7 0.0111
Cervical mediastinoscopy 12 5.66 9 5.92 0.976
EUS/EBUS 52 24.5 46 30.2 0.305
MR brain 37 17.5 47 30.9 0.005
Bone scintigraphy 9 4.24 2 1.31 0.097
Thoracocentesis 28 13.2 21 13.8 0.962
Bronchoscopy 142 67.0 101 66.5 0.596
X-ray guidance bronchoscopy 33 15.6 24 15.8 0.941
CT guided biopsy 25 11.8 31 20.3 0.035
X-thorax after biopsy 23 10.8 13 8.55 0.411
VO2 max 23 10.8 17 11.2 0.995
Broad lung function 137 64.6 68 44.7 <0.001
Flow volume 1 0.47 34 22.4 <0.001
Ventilation / perfusion scan 19 8.96 11 7.24 0.497
ECG 98 46.2 125 82.2 <0.001
KRAS / EGFR 64 30.2 41 27.0 0.391
ALK 8 3.77 15 8.55 0.023
https://doi.org/10.1371/journal.pone.0189251.t002
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Two populations are studied from two different hospitals, one large academic center (162
of 407 patients in the province) and one large regional teaching hospital (214 of 713 patients in
the province) [17]. This gives insight and could not be generalized to all other hospitals but to
those who have a situation alike. A large difference in adherence to CPG’s in these two centers
can be seen with the usage rates for PET/CT, brain MRI and advances in novel tests such as
mutation analysis (detection of ALK translocations in tumor tissue). The deviation in usage
rate for PET/CT can be explained by the fact that the regional hospital had to refer patients to
a different location for the PET/CT. This difference in availability between centers could lead
to a cost difference.
Deviations can also occur due to usage of more diagnostic procedures than sometimes nec-
essary, which can be seen in different usage rates in PET/CT, diagnostic CT, CT guided biopsy,
cardiac and lung function tests. In general, about 18 tests are performed in individual patient
to diagnose and have functional information whether procedures, surgery, targeted therapy or
chemotherapy can be performed. But it also means that even with CPG’s there is practice vari-
ability due to variability in patients characteristics.
A limitation in our data is the fact that not all diagnostics carried out for referred patients to
the academic center are listed, because we did not have access to the files at the original hospi-
tal. Patients are selected through the dataset of the Netherlands Cancer Registry, hosted by the
Netherlands Comprehensive Cancer Organisation, which registers all patients whom are diag-
nosed with lung cancer in the year 2012 in both hospitals. However, these patients represent
the true positives, i.e. those with confirmed lung cancer. Patients suspicious of lung cancer
who finally appear false-positive cannot be identified through the cancer registry. However, it
should be acknowledged that this group is an important group to calculate the overall budget
impact of the lung cancer diagnostic pathway. As mentioned above, a dataset of patients with
lung cancer in 2012 is used. The Dutch guidelines did not change since 2011 apart from a
minor addition in the detection of oncogenic abnormalities. The authors therefore chose this
dataset, because full data access was granted.
Table 3. Procedure and test tariffs (2014).
Modality DBC procedure code Tariff (€) Hospital costs (€)
X-thorax 85002 43.66 36.19
CT-thorax 85042 182.21 132.19
PET/CT 120501 1162.93 951.29
EUS/EBUS 34386/34387 791.15 622.59
Mediastinoscopy 29099045 2430.00 2430.00
Brain MR 81092 218.29 173.21
Thoracocentesis 32684 50.50 50.50
Bronchoscopy 32480 370.71 370.71
X-ray guidance 85000 53.14 48.66
CT-guided biopsy 80047 229.63 162.42
VO2 max 39844 170.38 88.13
Flow volume + diffusion 39932 67.60 67.60
Flow volume 39839 33.11 33.11
Ventilation/perfusion scan 120060 225.78 165.31
ECG 39757 26.83 26.83
Mutation analysis KRAS/EGFR 50512 951.54 905.18
Translocation analysis ALK 50514 449.30 393.57
Note: DBC procedure code are the codes used in the Netherlands for reimbursement.
https://doi.org/10.1371/journal.pone.0189251.t003
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Due to the increasing age of the population and the increase in incidence of lung cancer, it
is expected the need for diagnostic procedures will dramatically impact the health system.
Hence, this will result to an increase in resources and thus higher budget impact. For that rea-
son, there is an increased need for a sustainable diagnostic pathway for suspected lung cancer
patients.
The adherence to the CPG’s differ in the two hospitals, which questions the adherence to
CPG’s in general. Guideline adherence in the diagnostic workup has been questioned before
in other settings, for instance the use of an MRI prior to breast surgery. This study showed
considerable hospital variation in the use of a breast MRI (range 4–84%)[18]. This has also
been shown in a large cohort study of 15.951 lung cancer patients, of which 40% did not
receive adequate guideline-concordant care[19].
Overuse or misuse of diagnostic modalities can lead to a high burden on the budget impact.
Adherence to CPG’s could lead to less costs in the diagnostic pathway for lung cancer patients.
A more thorough evaluation into all applied tests is needed in a larger population to have
more accurate data on costs and their regional variation.
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